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Abstract
Purpose:  To  study  long-term  results  of  MyoRing  treatment  of  keratoconus.
Methods:  Retrospective  study  of  MyoRing  implantation  into  a  corneal  pocket  for  keratoconus.
Results: Corneal  thickness  at  the  thinnest  point  remained  unchanged,  SIM  K’s,  manifest  sphere
and cylinder  were  signiﬁcantly  improved  at  the  ﬁrst  follow-up  9  months  postoperatively  and
remained  stable  until  the  last  follow-up  about  5  years  after  surgery.  Uncorrected  and  cor-
rected distance  visual  acuity  (UDVA,  CDVA)  were  signiﬁcantly  improved  at  the  ﬁrst  follow-up
9 months  postoperatively  and  were  further  ameliorated  until  the  last  follow-up  about  5  years
after surgery.
Conclusion:  The  treatment  was  safe  and  effective  with  continuing  improvement  of  visual  acuity
during the  5  years  after  surgery.
© 2016  Published  by  Elsevier  España,  S.L.U.  on  behalf  of  Spanish  General  Council  of  Optometry.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).PALABRAS  CLAVE Resultados  a  largo  plazo  del  tratamiento  del  queratocono  con  MyoRing
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Resumen
Objetivo:  Estudiar  los  resultados  a  largo  plazo  del  tratamiento  del  queratocono  con  MyoRing.
Método:  Estudio  retrospectivo  de  la  implantación  del  MyoRing  en  un  bolsillo  corneal  en  los  casos
de queratocono.
 The study was partly supported by the Austrian Research Fund (FFG). Dr. Daxer has an investment interest in DIOPTEX GmbH, Dr. EttlPlease  cite  this  article  in  press  as:  Daxer  A,  et  al.  Long-term  results  of  MyoRing  treatment  of  keratoconus.  J  Optom.
(2016),  http://dx.doi.org/10.1016/j.optom.2016.01.002
and Dr. Hörantner have no ﬁnancial interest. Preliminary results were presented at the Keratoconus Expert Meeting held during the Annual
Meetings of the ESCRS 2014 in London and 2015 in Barcelona.
∗ Corresponding author at: Stauwerkstrasse 1, A-3370 Ybbs, Austria.
E-mail address: daxer@gutsehen.at (A. Daxer).
http://dx.doi.org/10.1016/j.optom.2016.01.002
1888-4296/© 2016 Published by Elsevier España, S.L.U. on behalf of Spanish General Council of Optometry. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Resultados:  El  espesor  de  la  córnea  en  el  punto  más  ﬁno  no  reﬂejó  cambios,  mejorando  los
valores de  SIM  K,  esfera  y  cilindro  maniﬁesto  durante  el  seguimiento  a  los  9  meses  de  la  inter-
vención y  permaneciendo  entonces  estables  hasta  el  último  seguimiento  a  los  5  an˜os  de  la
misma. La  agudeza  visual  no  corregida  y  corregida  (UDVA,  CDVA)  mejoró  considerablemente
a los  9  meses  de  la  intervención,  y  continuaron  mejorando  signiﬁcativamente  hasta  el  último
seguimiento  a  los  5  an˜os  de  la  misma.
Conclusión:  El  tratamiento  resultó  seguro  y  efectivo,  con  mejora  continua  de  la  agudeza  visual
durante los  5  an˜os  posteriores  a  la  cirugía.
© 2016  Publicado  por  Elsevier  España,  S.L.U.  en  nombre  de  Spanish  General  Council  of  Optome-
try. Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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eratoconus  is  a  rare  disease  which  is  characterized  by
rogressive  steepening  and  thinning  of  the  cornea,  thus
esulting  in  progressive  vision  loss.1 Corneal  intrastromal
mplantation  surgery  (CISIS)  with  MyoRing  implantation  has
emonstrated  to  be  an  effective  and  safe  treatment  for
isual  rehabilitation  in  myopia  and  keratoconus.2,3 This
aper  presents  5  years  follow-up  data  of  MyoRing  treatment
or  keratoconus  of  a  central  European  population,  discusses
he  related  treatment  principles  and  provides  a  guideline
or  evaluating  treatment  success.
aterials and methods
s  described  elsewhere,2,3 CISIS  starts  with  the  creation
f  an  intrastromal  corneal  pocket  of  9  mm  in  diameter
t  a  depth  of  300  microns  by  means  of  the  PocketMaker
ltrakeratome  (DIOPTEX  GmbH,  Austria),  followed  by  the
mplantation  of  the  MyoRing  (DIOPTEX  GmbH,  Austria)  via  a
mall  lamellar  tunnel  of  less  than  5.5  mm  using  a  particular
mplantation  forceps.  The  MyoRing  ﬁnally  has  to  be  centered
y  using  the  real  postoperative  optical  axis  as  a  reference.
he  lamellar  tunnel  is  self-sealing  and  requires  no  suture.
he  procedure  is  minimally  invasive,  causes  no  pre-  or  post-
perative  pain  and  will  take  only  10  min  when  performed  by
 trained  and  experienced  surgeon.
Postoperatively,  the  eye  requires  neither  bandage  lenses
or  patching.  The  patient  is  advised  to  apply  a  combination
f  steroid  and  antibiotic  eye  drops  hourly  until  undergo-
ng  the  ﬁrst  follow-up  exam  on  the  ﬁrst  postoperative  day.
etween  this  ﬁrst  postoperative  exam  until  two  week  after
urgery,  the  patient  is  advised  to  reduce  the  application
f  the  aforementioned  combination  of  eye  drops  to  merely
 times  a  day.  Thereafter  no  further  medical  therapy  is
equired.  The  next  follow-up  exam  is  usually  performed
 months  after  surgery  to  evaluate  whether  the  result  is
lready  optimal  or  may  be  further  enhanced.  This  is  called
he  initial  postoperative  observation  period.
According  to  the  suggested  visual  potential  of  the  individ-
al  eye,  some  20%  of  the  patients  draw  a  visual  beneﬁt  fromPlease  cite  this  article  in  press  as:  Daxer  A,  et  al.  Long-term
(2016),  http://dx.doi.org/10.1016/j.optom.2016.01.002
 simple  postoperative  enhancement.4 The  enhancement
s  performed  either  by  optimizing  the  position  in  relation
o  the  real  postoperative  optical  axis  or  by  exchanging  the
yoRing  for  one  with  different  dimensions.  An  enhancement
R
5
ts  accomplished  easily  and  takes  usually  less  than  one  minute
ithout  causing  the  patient  intra-  or  postoperative  pain.
This  iterative  optimization  procedure  is  based  on  the
ationale  that  an  a  priori  clinical  determination  of  all  infor-
ation  required  for  a  nomogram  that  predicts  the  initial
esult  in  100%  of  the  cases  is  simply  impossible  in  the  in  vivo
orneal  system.  In  other  words,  complex  nomograms  with
any  decision  criteria  suggest  a  nomogram  accuracy  to  the
ser  which  is  completely  unreal.  In  the  case  of  MyoRing
reatment,  the  accuracy  of  the  nomogram  therefore  reﬂects
he  real  accuracy  of  the  maximum  possible  degree  of  deter-
ination  of  the  corneal  system.  This  results  in  some  20%  of
atients  who  beneﬁt  from  a  simple  enhancement  3  months
fter  initial  surgery.  In  other  words,  if  the  prediction  accu-
acy  of  a  system  is  80%  for  the  initial  approach,  it  only  takes  a
imple,  short  and  safe  procedure  for  further  enhancement  in
 second  step  to  achieve  a  success  rate  of  nearly  100%.  This
s  exactly  the  philosophy  behind  the  MyoRing  treatment.4
In  this  retrospective  study,  two  postoperative  follow-ups
er  patient  have  been  included:  the  ﬁrst  one  approxi-
ately  one  year  after  the  last  surgical  intervention  and  the
econd  one  approximately  5  years  later.  The  examination
erformed  at  the  end  of  both  follow-up  periods  used  for
he  study  included  Scheimpﬂug  measurement  for  topogra-
hy,  pachymetry  at  the  thinnest  point  (ct)  and  K-readings
IM  K1,  SIM  K2  and  K  =  (SIM  K1  +  SIM  K2)/2  using  the  Penta-
am  (Oculus  GmbH,  Germany),  uncorrected  distance  visual
cuity  (UDVA)  and  corrected  distance  visual  acuity  (CDVA).
isual  acuity  data  are  represented  in  logMAR.
Statistical  evaluation  was  performed  using  the  two-tailed
aired  t-test  for  comparison  of  data  having  Gaussian  dis-
ribution.  The  normality  testing  for  Gaussian  distribution
as  performed  using  the  D’Agostino  &  Pearson  omnibus  nor-
ality  test.  In  the  case  of  non-Gaussian  data  distribution,
he  data  were  compared  using  the  Wilcoxon  matched-pairs
igned  rank  test.  To  qualify  data  as  being  signiﬁcantly  dif-
erent  in  statistical  terms,  a  p-value  of  less  than  0.05  was
sed.  The  statistical  data  are  presented  in  mean  ±  standard
rror  (se)  in  the  case  of  Gaussian  distribution  and  as  median
nd  range  in  case  the  normality  test  was  not  passed. results  of  MyoRing  treatment  of  keratoconus.  J  Optom.
esults
3  eyes  of  patients  pertaining  to  a  Central  European  popula-
ion  from  all  over  Austria  and  Germany  were  treated  within
 IN+Model
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MyoRing  for  keratoconus  
the  selected  period.  A  subgroup  of  17  eyes  of  13  patients  ful-
ﬁlled  the  criteria  of  having  2  independent  follow-up  exams
within  the  selected  follow-up  periods  with  all  required
data  available  (corneal  thickness,  topography  including  K-
readings,  manifest  refraction,  uncorrected  distance  visual
acuity  UDVA,  corrected  distance  visual  acuity  CDVA).  Many
patients  had  to  cover  a  long  distance  of  sometimes  more
than  1000  km  for  examination  in  our  center.  The  majority  of
that  patients  refused  to  spend  two  days  and  a  ﬂight  for  long-
term  follow-up  examination  when  they  were  happy  with  the
results.  The  study  had  to  be  limited  to  patients  representing
a  homogenous  ethnic  group  (central  European  population)  to
rule  out  an  inﬂuence  resulting  from  ethnic  variations.  The
nomograms  of  patients  from  the  Middle  East,  for  example,
must  be  different  from  those  used  for  European  popula-
tions  to  avoid  overcorrections.4 The  ﬁrst  follow-up  exam
performed  in  the  eyes  included  in  the  study  was  between
3  months  and  24  months  after  surgery  (9  ±  1.8).  The  sec-
ond  follow-up  exam  was  between  36  months  and  90  months
after  surgery  (56  ±  3.9).  10  eyes  were  right  eyes  (OD)  and  7
were  left  eyes  (OS).  Two  patients  (4  eyes)  were  female  and
11  patients  (13  eyes)  were  male.  The  age  of  the  patients
at  the  time  of  surgery  ranged  from  21  to  50  years  (median
35  years).  Of  the  17  eyes  3  (17.5%)  had  grade  I,  4  (23%)
had  grade  II,  5  (30%)  had  grade  III,  3  (17.5%)  had  grade  IV
and  2  (12%)  had  grade  V  according  to  the  grading  after  Alio
et  al.5 A  minimum  of  3  eyes  (17%)  experienced  progression
of  the  disease  in  the  year  prior  to  surgery.  Four  of  the  17
eyes  (23.5%)  had  an  enhancement  intervention  3  months
after  the  initial  treatment,  during  which  the  implant  was
replaced  by  a  stronger  or  weaker  one.  For  these  4  eyes,  the
postoperative  follow-up  period  started  with  the  date  when
the  enhancement  was  performed.  No  eye  underwent  more
than  one  enhancement  procedure.  All  surgeries  were  per-
formed  by  one  surgeon  (A.D.)  and  did  not  result  in  any  intra-
or  postoperative  complications.
The  corneal  thickness  measured  at  the  thinnest  point
showed  no  statistically  signiﬁcant  changes  at  both  follow-
ups  compared  to  the  preoperative  value  or  compared  to
the  other  postoperative  value.  Fig.  1a  shows  the  graphi-
cal  representation.  The  values  for  corneal  thickness  were
440  ±  9  microns  preoperatively,  445  ±  8  microns  at  the  ﬁrst
follow-up  and  442  ±  7  microns  at  the  second  follow-up,
respectively.
The  average  central  K-value  determined  by  K  =  (SIM
K1  +  SIM  K2)/2  was  signiﬁcantly  lower  than  the  preoperative
value  of  50.68  ±  1.1  diopters  (D)  at  both  follow-ups.  No  sig-
niﬁcant  changes  occurred  between  the  ﬁrst  (45.27  ±  0.88  D)
and  second  postoperative  follow-up  (45.76  ±  0.74  D).  Fig.  1b
shows  the  time  course  of  K.
The  manifest  sphere  (sph)  as  well  as  the  cylinder
(cyl)  were  signiﬁcantly  reduced  at  both  follow-ups  com-
pared  to  the  preoperative  value  (sph  −5.21  ±  1.13  D,
cyl  −4.79  ±  0.39  D).  However,  no  signiﬁcant  change  was
observed  between  the  ﬁrst  postoperative  follow-up  (sph
−1.25  ±  0.48  D,  cyl  −1.46  ±  0.30  D)  and  the  second  follow-
up  (sph  −0.93  ±  0.52  D,  cyl  −1.18  ±  0.31  D)  (Fig.  1c  and  d).
Uncorrected  distance  visual  acuity  (UDVA)Please  cite  this  article  in  press  as:  Daxer  A,  et  al.  Long-term
(2016),  http://dx.doi.org/10.1016/j.optom.2016.01.002
improved  signiﬁcantly  between  the  preoperative  exam
(1.58  ±  0.38  logMAR)  and  the  ﬁrst  postoperative  follow-up
(0.30  ±  0.041  logMAR),  as  was  the  case  between  the  pre-
operative  exam  and  the  second  postoperative  follow-up
t
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0.22  ±  0.038  logMAR).  UDVA  also  improved  signiﬁcantly
etween  both  postoperative  follow-up  examinations.
ig.  1e  shows  the  time  course  of  UDVA,  demonstrating  an
mprovement  of  some  12  lines  on  average.  All  eyes  gained
ines  at  both  postoperative  follow-ups  when  compared  to
he  preoperative  state.
Corrected  distance  visual  acuity  (CDVA)  had  no  Gaussian
istribution  in  the  preoperative  exam  nor  after  both  post-
perative  follow-up  periods  because  the  average  natural
imit  for  improvement  at  20/20  (0.0  logMAR)  is  closer  to  the
easured  CDVA  values  when  compared  to  UDVA.  The  pre-
perative  median  of  CDVA  was  0.4  logMAR  (range  0.22--1.0).
he  median  of  CDVA  at  the  ﬁrst  follow-up  was  0.15  (range
.0--0.52),and  at  the  second  follow-up  0.1  (range  0.0--0.4),
espectively.  CDVA  was  statistically  different  in  all  3  exam-
nations.  A  particular  improvement  of  CDVA  was  observed
etween  the  preoperative  exam  and  the  ﬁrst  postopera-
ive  follow-up;  a further  signiﬁcant  improvement  was  seen
etween  the  ﬁrst  and  second  postoperative  follow-up.  The
elated  graph  in  Fig.  1f  demonstrates  an  improvement  of
pproximately  2--3  lines  on  average.  All  eyes  gained  lines
nd  no  eye  lost  lines  in  the  two  postoperative  follow-ups
ompared  to  the  preoperative  state.
Fig.  2  shows  the  line  improvement  of  uncorrected  and
orrected  distance  visual  acuity  as  a  function  of  the  severity
f  the  disease  measured  as  preoperative  visual  acuity.  This
akes  sense  as  the  potential  for  improvement  is  different
or  mild  and  advanced  cases;  mild  cases  require  fewer  lines
o  reach  20/20  than  advanced  ones.  The  same  is  true  when
omparing  UDVA  and  CDVA:  the  improvement  potential  for
DVA  is  less  than  for  UDVA.
Fig.  2a  shows  the  line  improvement  of  UDVA  at  ﬁrst
nd  second  follow-up  compared  to  preoperative  UDVA  as
 function  of  preoperative  UDVA.  Fig.  2b  shows  the  line
mprovement  of  CDVA  at  ﬁrst  and  second  follow-up  com-
ared  to  preoperative  CDVA  as  a function  of  preoperative
DVA.  The  dashed  lines  are  the  result  of  the  linear  regression
f  line  improvement  in  UDVA  (r2 =  0.8865,  y =  8.844x −  1.21,
ig.  2a)  and  CDVA  (r2 =  0.5591,  y  = 6.69x −  0.53,  Fig.  2b)
t  the  ﬁrst  postoperative  follow-up  (open  circles).  The
olid  lines  are  the  result  of  the  linear  regression  of  the
ine  improvement  of  UDVA  (r2 =  0.8992,  y  =  8.691x −  0.114,
ig.  2a)  and  CDVA  (r2 =  0.7588,  y  =  7.0x  +  0.17,  Fig.  2b)  at  the
econd  postoperative  follow-up  (black  circles).  Some  data
oints  are  overlaid  by  others  in  Fig.  2.  The  dotted  lines  rep-
esent  the  maximum  possible  (ideal)  improvement  to  20/20
isual  acuity.  In  UDVA  and  particularly  in  CDVA,  visual  acuity
dditionally  improves  between  the  ﬁrst  and  second  follow-
p;  this  improvement  is  indicated  by  a shift  of  the  linear
egression  line  toward  the  ideal  (dotted)  line.
iscussion
he  results  of  the  present  study  show  a  signiﬁcant  improve-
ent  of  K-reading,  sphere  and  cylinder  as  well  as  UDVA
nd  CDVA  after  MyoRing  implantation  in  keratoconus  at results  of  MyoRing  treatment  of  keratoconus.  J  Optom.
he  ﬁrst  follow-up  approximately  9  months  after  surgery.
hile  K-reading,  sphere  and  cylinder  remain  unchanged
etween  the  ﬁrst  and  the  second  follow-up  around  5  years
fter  surgery,  UDVA  and  CDVA  show  a  continued  statistically
ARTICLE IN PRESS+ModelOPTOM-178; No. of Pages 7
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tigure  1  shows  the  time  course  of  corneal  thickness  (a),  cen
e) and  CDVA  (f).  Error  bars  represent  standard  error  of  mean.
igniﬁcant  improvement  during  this  second  postoperative
eriod  (Figs.  1  and  2).
The  statistically  signiﬁcant  improvement  of  UDVA  and
DVA  even  during  the  long-term  postoperative  period  not
nly  indicates  a  signiﬁcant  degree  of  visual  rehabilitation
ut  may  also  indicate  a  stabilization  of  the  diseased  cornea
ollowing  MyoRing  implantation.  Moreover,  the  continuous
mprovement  in  CDVA  during  the  postoperative  course  in
ll  grades  of  the  disease  (Fig.  2)  points  at  an  ongoing  post-Please  cite  this  article  in  press  as:  Daxer  A,  et  al.  Long-term
(2016),  http://dx.doi.org/10.1016/j.optom.2016.01.002
perative  ‘‘regularization  process’’  of  the  diseased  cornea
fter  treatment.  The  average  visual  improvement  of  12
ines  and  more  in  UDVA  and  3  lines  in  CDVA  correlates  with
arlier  reports  which  consider  one-year  follow-ups  after
t
t
c
y-reading  (b),  manifest  sphere  (c),  manifest  cylinder  (d),  UDVA
reatment.3 This  data  is  in  striking  contrast  to  the  data
btained  from  ring  segments,  which  hardly  reach  compa-
able  improvements  in  visual  acuity.6--8
Ring  segments  have  the  disadvantage  of  resulting  in  a
ong-term  postoperative  loss  of  visual  acuity.9,10 MyoRing
mplantation,  by  contrast,  stabilizes  the  corneal  thickness
ven  in  previously  progressive  cases,  as  several  reports
ndicate.11--13 None  of  the  3  eyes  (17%)  in  the  present  study
hat  had  documented  progression  during  the  year  prior  to results  of  MyoRing  treatment  of  keratoconus.  J  Optom.
reatment  did  so  after  MyoRing  insertion.  However,  since
he  keratoconic  cornea  of  an  individual  patient  can  only  be
haracterized  as  progressive  through  a  retrospective  anal-
sis,  it  is  generally  impossible  to  qualify  such  a  cornea  as
ARTICLE IN+ModelOPTOM-178; No. of Pages 7
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Figure  2  shows  line  improvement  versus  preoperative  visual
acuity.  (a)  Line  improvement  in  UDVA  vs.  preoperative  UDVA  lin
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treatment  pursues  a  different  strategy  than  ring  segmentslogMAR.  (b)  Line  improvement  in  CDVA  vs.  preoperative  CDVA  in
logMAR.
progressive.  In  other  words,  if  a  cornea  was  progressive  in
the  recent  past  but  is  no  longer  progressive  after  treatment,
there  may  be  two  possibilities:  either  the  past  progression
and  future  halting  of  progression  is  the  natural  course  of  the
disease  or  the  treatment  is  effective  and  stops  progression.
Another  possibility  is  that  the  disease  is  not  progressive  at  a
certain  point  of  time  but  becomes  progressive  in  the  future.
Therefore,  the  efﬁcacy  of  a  therapy  in  halting  keratoconus
progression  cannot  be  evaluated  by  simply  comparing  two
groups  of  cases  in  terms  of  their  past  individual  behavior:
progressive  and  non-progressive.  Moreover,  it  is  necessary
to  compare  a  treated  group  with  a  similar  group  not  under-
going  treatment,  and  to  relate  the  number  of  patients  that
would  have  progressed  during  the  follow-up  period  without
treatment  to  those  who  progressed  after  treatment.  Lon-Please  cite  this  article  in  press  as:  Daxer  A,  et  al.  Long-term
(2016),  http://dx.doi.org/10.1016/j.optom.2016.01.002
gitudinal  studies  show  a  progression  rate  of  approximately
25%  in  patients  with  an  average  age  of  25  years  suffering
from  mild  to  moderate  keratoconus.14 Considering  that  the
a
r
p PRESS
5
opulation  included  in  the  present  study  has  a  higher  aver-
ge  age  (35  years)  and  the  percentage  of  documented  cases
howing  progression  immediately  prior  to  treatment  was
7%,  it  can  be  estimated  that  approximately  20%  of  the  eyes
ould  have  progressed  during  the  average  follow-up  period
f  5  years  without  treatment.  The  estimation  is  based  on  the
ssumption  that  at  least  one  eye  out  of  the  preoperatively
ot  progressing  eyes  is  likely  to  progress  during  the  5  year
bservation  period  but  counting  it  just  with  50%  probability.
The  fact  that  no  signiﬁcant  progression  was  observed  in
he  present  study  after  MyoRing  treatment  during  an  aver-
ge  follow-up  period  of  some  5 years  is  no  total  proof  that
yoRing  implantation  stops  progression,  but  it  is  a  very
trong  indicator.  One  explanation  for  the  stop  of  progression
f  keratoconus  after  MyoRing  implantation  may  be  found
n  the  biomechanics  of  the  cornea  before  and  after  MyoR-
ng  implantation.15 Since  the  MyoRing  is  a  continuous  full
ing  implant,  with  no  disruption  of  continuity  along  its  cir-
umference,  it  acts  in  the  cornea  like  a  second  (artiﬁcial)
imbus  and  supports  the  cornea  biomechanically  in  much  the
ame  way  as  a  ceiling  beam  supports  the  ceiling  of  a  room
nder  load  by  separating  the  ceiling  (cornea)  into  two  com-
artments  and  reducing  the  load  on  each  compartment.15
peciﬁcally,  the  MyoRing  is  able  to  take  up  a  signiﬁcant
mount  of  the  load  acting  on  the  cornea.  This  mechanism
ay  result  in  a  strengthening  of  the  cornea  by  a  factor
f  3  after  MyoRing  implantation,  which  corresponds  to  an
ncrease  in  effective  corneal  thickness  of  a  factor  of  3.  A
iscontinuous  ceiling  beam  (in  analogy  to  ring  segments),  in
urn,  is  unable  to  stabilize  a  ceiling  under  load.15
Another  important  difference  between  ring  segments  and
he  MyoRing  is  that  the  MyoRing  provides  the  surgeon  with
ll  three  possible  degrees  of  freedom  to  achieve  the  optimal
esult  in  any  given  case  (implant  thickness,  implant  diameter
nd  implant  position),  whereas  ring  segments  provide  only
ne  degree  of  freedom  (implant  thickness).16 Speciﬁcally,
he  position  of  the  segment  is  determined  by  the  preparation
f  the  circular  tunnel  relating  to  the  preoperative  ﬁxation
optical  axis),  which  in  turn  depends  on  the  preoperative
orneal  shape.  In  this  context,  it  is  important  to  understand
hat  the  misalignment  of  an  implant  by  about  0.5  mm  may
ave  a  dramatic  impact  on  the  visual  results.17 The  MyoRing
s  placed  inside  a  corneal  pocket  with  a  diameter  of  9  mm,
hich  allows  to  align  the  implant  to  the  postoperative  ﬁxa-
ion  of  the  eye  at  the  end  of  the  surgical  intervention.  This
ay  be  a  further  reason  why  MyoRing  implantation  outper-
orms  ring  segments  in  terms  of  vision  improvement.
To  be  able  to  exploit  the  full  potential  of  the  MyoRing,
t  is  also  important  to  understand  the  natural  boundaries
f  a  nomogram  in  predicting  the  perfect  implant  dimension
n  any  speciﬁc  situation  and  to  draw  the  right  conclusion
rom  this  understanding.  While  the  nomogram  for  the  MyoR-
ng  treatment  of  keratoconus  is  very  simple  (it  depends
nly  on  the  average  SIM  K),  the  nomograms  for  ring  seg-
ents  tend  to  be  much  more  complex  yet  often  do  not
llow  a satisfactory  prediction  of  the  results.17,18 It  seems
hat  ring  segment  nomograms  overestimate  the  biomechan-
cal  predictability  for  keratoconic  corneas  in  vivo.  MyoRing results  of  MyoRing  treatment  of  keratoconus.  J  Optom.
nd  tries  to  avoid  pseudo-accuracy  in  the  nomogram.  The
ationale  of  MyoRing  treatment  is:  If  a  system  cannot  be
redicted  preoperatively  with  100%  accuracy,  the  surgical
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that  the  implant  has  a  larger  diameter  and/or  is  thinner,
‘‘stronger’’  means  the  opposite.  The  rationale  of  MyoRing
treatment  of  keratoconus  for  achieving  optimal  results  is
somehow  related  to  hard  contact  lens  ﬁtting.  But  instead
of  analyzing  ﬂuorescein  patterns  as  in  contact  lens  ﬁtting,
the  MyoRing  is  optimally  adjusted  to  match  the  tangential
topography  map.
As  sometimes  seen  in  MyoRing-treatment  videos  (e.g.  on
YouTube),  another  mistake  is  to  ‘‘mark’’  the  cornea  prior  to
implantation  for  the  purpose  of  aligning  the  MyoRing.  This
procedure  does  not  allow  to  achieve  the  best  possible  result
in  each  individual  case  because  optimal  treatment  requires
alignment  to  the  real  postoperative  ﬁxation.  The  best  results
are  achieved  when  the  surgical  microscope  has  a  concentric
light-source  which  the  patient  can  ﬁxate.  At  the  end  of  the
surgical  intervention,  once  the  MyoRing  has  been  implanted
into  the  corneal  pocket,  the  patient  is  asked  to  ﬁxate  this
light  source.  Then  the  MyoRing  is  shifted  to  its  ‘‘central’’
Nomogram MyoRing selection
MyoRing implantation
3 months observation period
Best possible result achieved?
No
Enhancement
Yes
Treatment finishedigure  3  shows  the  tangential  topographic  map  of  3  differ
ermany): (a)  perfect  result,  (b)  overcorrection  and  (c)  underc
pproach  has  to  be  designed  in  such  a  way  that  it  becomes
xtremely  simple  to  enhance  the  result  in  a  certain  per-
entage  of  cases  postoperatively,  and  this  enhancement
rocedure  is  then  incorporated  into  the  treatment  strategy.
onsequently,  MyoRing  treatment  is  based  on  a  lamellar  sur-
ical  concept  focusing  on  a  small  lamellar  incision  that  does
ot  require  suturing.  The  replacement  of  a  MyoRing  implant
s  a  one-minute  job  which  causes  no  pain  or  irritation.  Clin-
cal  problems  during  or  after  MyoRing  exchange  have  not
een  observed.  The  costs  for  exchanging  the  implant  after  3
onths  is  covered  by  the  initial  payment  of  the  patient  --  so
he  patient  do  not  have  to  pay  extra  for  that.  In  the  present
tudy,  4  out  of  17  MyoRings  (23.5%)  were  replaced  after  the
nitial  postoperative  observation  period  of  three  months  to
chieve  optimal  individual  results.  The  results  are  indepen-
ent  of  cone  position  (central  or  non-central)  because  the
yoRing  inside  a  corneal  pocket  automatically  ‘‘corrects’’
he  corneal  area  in  the  right  way.19
The  criteria  for  optimization,  i.e.  the  need  to  change
he  implant  for  a  ‘‘stronger’’  or  ‘‘weaker’’  one,  may  differ
epending  on  the  following  situations.  If  visual  acuity  (UDVA,
DVA)  at  the  end  of  the  postoperative  observation  period
f  three  months  is  as  preoperatively  planned,  no  further
ntervention  is  needed  and  treatment  is  completed.  In  these
ases,  the  refraction  (spherical  equivalent  SE)  is  normally
lose  to  zero  and  the  topography  shows  a  certain  character-
stic  pattern  in  the  postoperative  tangential  map  (Fig.  3a);
he  color-marked  local  corneal  curvature  has  the  shape  of
 ‘‘central  island’’  and  the  ring-shaped  topography  of  the
yoRing  is  of  ‘‘homogeneous’’  intensity  (local  curvature).
f  visual  acuity  at  the  end  of  the  postoperative  observation
eriod  of  three  months  does  not  match  preoperative  expec-
ations,  refraction  and  topography  will  have  to  play  a  role
n  further  decision  making.  In  the  case  of  overcorrection,
he  refraction  shows  a  hyperopic  shift  and  the  color-marked
‘intensity’’  of  the  concentric  ring  in  the  tangential  map
s  most  pronounced  over  the  ‘‘central  island’’  (Fig.  3b).  In
his  case,  the  MyoRing  has  to  be  replaced  by  a  ‘‘weaker’’
ne.  The  opposite  applies  in  the  case  of  undercorrection.
ere  the  spherical  equivalent  is  usually  in  the  myopic  range,Please  cite  this  article  in  press  as:  Daxer  A,  et  al.  Long-term  results  of  MyoRing  treatment  of  keratoconus.  J  Optom.
(2016),  http://dx.doi.org/10.1016/j.optom.2016.01.002
nd  the  prominent  feature  in  the  tangential  map  is  the
‘central  island’’,  with  the  concentric  ring  pattern  being
learly  underrepresented  (Fig.  3c).  This  is  an  indication  to
eplace  the  implant  by  a  ‘‘stronger’’  one.  ‘‘Weaker’’  means
Figure  4  shows  the  treatment  strategy  for  achieving  optimal
individual  results.  The  criteria  for  deciding  whether  or  not  an
optimal individual  result  is  achieved  are  described  and  discussed
in detail  in  the  discussion  section.
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position  inside  the  pocket  (between  the  center  of  the  pupil
and  the  central  spot  between  the  ﬁrst  and  the  second  Pur-
kinje  Reﬂex  of  the  concentric  microscope  light  source).  This
procedure  also  helps  to  minimize  the  paralaxis  error  and  to
properly  determine  the  center  of  the  pupil.
To  be  able  to  assess  the  individual  results  of  MyoRing
treatment  achieved  by  a  speciﬁc  surgeon,  it  is  necessary
to  use  a  plot  like  the  one  in  Fig.  2  allows  to  analyze  the
results,  including  the  surgeon’s  speciﬁc  performance,  in
detail.  This  performance  can  be  assessed  for  mild,  moderate
and  advanced  cases  (Fig.  4).
In  conclusion,  the  MyoRing  --  when  used  according  to  the
treatment  principles  described  above  --  has  the  potential  to
produce  excellent  long-term  vision  results  in  mild,  moderate
and  advanced  keratoconus  cases,  regardless  of  cone  position
and  disease  progression.
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